A study of nearly 1,500 patients treated for kidney cancer at UCLA in the last 15 years shows that an aggressive, tailored treatment approach results in better survival rates and uncovered subsets of kidney cancer that behave differently and need to be treated accordingly.

Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ.

Patients in the United States today are now much more likely to be diagnosed with smaller tumors, in the earliest, most treatable stage of kidney cancer than a decade ago, leading to a slightly higher survival rate, according to the results of a national study led by a UC San Diego Medical Center researcher.

New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.

A new study reveals that the type of surgery a patient with kidney cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health. The findings indicate that patients with kidney cancer often may not be receiving the most appropriate surgical care.

A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact. The study will be published in the February issue of the Journal of Urology.

A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue - a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.